Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pamapimod. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2015-07-24

Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-α in Whole Blood and Primary Cells from Different Species.

Fehr S, Unger A, Schaeffeler E, Herrmann S, Laufer S, Schwab M, Albrecht W.

Cell Physiol Biochem · research support, non-u.s. gov't; journal article · DOI 10.1159/000430188

Bibliografisk träff 2011-06-01

Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects.

Zhang X, Fettner S, Winter E, Masjedizadeh M, Hisoire G.

Int J Clin Pharmacol Ther · clinical trial; journal article · DOI 10.5414/cp201530

Bibliografisk träff 2011-03-04

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.

Goldstein DM, Soth M, Gabriel T, Dewdney N, Kuglstatter A, Arzeno H, Chen J, Bingenheimer W, Dalrymple SA, Dunn J, Farrell R, Frauchiger S, La Fargue J, Ghate M, Graves B, Hill RJ, Li F, Litman R, Loe B, McIntosh J, McWeeney D, Papp E, Park J, Reese HF, Roberts RT, Rotstein D, San Pablo B, Sarma K, Stahl M, Sung ML, Suttman RT, Sjogren EB, Tan Y, Trejo A, Welch M, Weller P, Wong BR, Zecic H.

J Med Chem · journal article · DOI 10.1021/jm101423y

Bibliografisk träff 2010-10-01

Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?

Doggrell SA, Christensen AM.

Expert Opin Pharmacother · comment; journal article · DOI 10.1517/14656566.2010.507631

Bibliografisk träff 2010-01-25

A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.

Zhang X, Huang Y, Navarro MT, Hisoire G, Caulfield JP.

J Clin Pharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1177/0091270009357433

Bibliografisk träff 2009-04-08

Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy.

Alten RE, Zerbini C, Jeka S, Irazoque F, Khatib F, Emery P, Bertasso A, Rabbia M, Caulfield JP.

Ann Rheum Dis · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1136/ard.2008.104802

Bibliografisk träff 2009-02-01

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.

Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP.

Arthritis Rheum · comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/art.24266

Bibliografisk träff 2008-09-05

Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.

Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.108.139006